Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing simple and easy-to-use tools for people with insulin-requiring diabetes, today announced the publication of a ...

Most patients usually administer their medication, which can range from swallowing pills to injecting insulin. But they do not always get it right, as noted by Vereityinfo. According to experts, ...

Researchers sought to evaluate the role of insulin administration method on glycemic control, hypoglycemia risk, treatment adherence, and quality of life in older adults with type 2 diabetes. To ...

Due to continuing patient safety problems, ISMP suggests hospitals stop using insulin pens in an inpatient setting, as they were originally intended for ambulatory care. “Other problems such as using ...

A new survey, published in The Joint Commission Journal on Quality and Patient Safety, examined insulin pen use in the inpatient setting. Insulin pens can offer several advantages, but there have also ...

Medtronic's launch of a new version of its smart insulin pen with integrated continuous glucose monitoring (CGM) is the first such "connected" device for use by people with diabetes who use multiple ...

Incorporating insulin into your daily life can take some getting used to. From packing your on-the-go bag to prepping your syringe or insulin pen, here are tips to get you started. Insulin may be one ...

Eli Lilly & Co. has signed a deal to link Welldoc’s digital health platform with its upcoming connected insulin devices and therapies. The two will collaborate on a new version of Welldoc’s ...

This morning medical device company Medtronic announced its plans to buy Companion Medical, which is best known for making the InPen, an insulin pen that integrates a companion app, for an undisclosed ...

Findings from a literature review indicate that overall costs of long-acting insulin analogues are not significantly different from those of intermediate-acting human insulin and oral antidiabetic ...